Ocugen Inc. has announced updates to its Retina Scientific Advisory Board and Executive Leadership Team. Vijay Tammara, PhD, has been appointed as the Chief Development Officer, bringing extensive experience in global regulatory leadership. The company also introduced three renowned retinal surgeons to its advisory board to enhance guidance as it develops gene therapies for retinal diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.